Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P48444
UPID:
COPD_HUMAN
Alternative names:
Archain; Delta-coat protein
Alternative UPACC:
P48444; B4E1X2; E9PEU4; Q52M80
Background:
The Coatomer subunit delta, also known as Archain or Delta-coat protein, plays a crucial role in cellular transport. It is a component of the coatomer complex, essential for protein transport from the ER to the Golgi and for maintaining Golgi structure. This protein binds to dilysine motifs and is involved in the retrograde Golgi-to-ER transport of proteins.
Therapeutic significance:
Linked to Short stature-micrognathia syndrome, Coatomer subunit delta's dysfunction highlights its potential in therapeutic strategies. The disease's skeletal phenotype suggests a role in collagen transport and secretion, offering a target for intervention.